ArticleClinicoEconomics and outcomes research : CEOR2017

Clinical and economic analysis of outcomes of dose tapering or withdrawal of tumor necrosis factor-α inhibitors upon achieving stable disease activity in rheumatoid arthritis patients.

Daniel Aletaha et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.